Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S0102 + S0105
- Development stage
- Preclinical
- Lead developer
- Singapore General Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravenous, Inhalation, Parenteral
01
Overview
S0102 + S0105 is an experimental, personalized bacteriophage cocktail consisting of two lytic bacteriophages, S0102 and S0105, both belonging to the *Tequintavirus* genus. Developed by researchers at Singapore General Hospital and Duke-NUS Medical School, this phage cocktail is designed to target and infect non-typhoidal Salmonella (NTS) strains. It has been investigated as an adjunct salvage therapy, administered intravenously, via nebulization, and through bilateral pleural instillation, in combination with antibiotics (such as meropenem) for the treatment of relapsed or refractory non-typhoidal Salmonella empyema in immunocompromised patients.
- Other names
- S0102 + S0105 bacteriophage cocktailS0102/S0105
Beyond the preview
Go deeper on S0102 + S0105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S0102 + S0105.